Alzheimer's disease drug not recommendedBMJ 1997; 315 doi: https://doi.org/10.1136/bmj.315.7115.1035f (Published 25 October 1997) Cite this as: BMJ 1997;315:1035
- Jacqui Wise
The first drug to be licensed in Britain for the symptomatic treatment of mild to moderately severe Alzheimer's disease has failed to be recommended by the Drug and Therapeutics Bulletin. The report produced by the Consumers' Association concluded: “On the published evidence available we cannot recommend the use of donepezil.”.
Donepezil (Aricept) is an acetylcholinesterase inhibitor that increases the concentration of acetylcholine at …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial